10月1日前调改完的承诺期限将至，西贝整改得怎么样了？ 根据其公布的调改方案，西贝已将儿童餐中的牛肉饼、鳕鱼条，还有羊肉串、猪排烩酸菜等9款核心菜 品，改为门店后厨现场制作，并全面启用非转基因大豆油作为烹调用油。 根据其小程序上的调改公示，到9月29日，九项调改内容中，应仅黄米凉糕一项还未完成。当天，凤凰 网《风暴眼》实地探访华北地区一家西贝莜面村，午餐高峰时间段门店可谓冷清，相比于半个月前开放 后厨探访时的"有问必答"，现在门店员工普遍表现谨慎：厨师长先通过员工告知后厨已不能探访，后 因"外出开会"全程未露面，对调改情况也未回应，普通员工对多数问题也仅以"不清楚""不知道"回应。 经历舆论风波，西贝似乎仍未找到与公众有效沟通的方式。从创始人贾国龙对罗永浩预制菜质疑的强硬 回应，到致歉信中"顾客虐我千百遍"的用词被指暗含情绪，再到一篇描述"七岁孩子哭诉吃不到西贝"的 文章引发全网嘲讽，西贝的舆论危机仍在发酵。 这场舆论海啸，是西贝自身经营问题的显性爆发，也是消费者对高价餐饮、预制菜疑虑、食品安全及信 息透明度长期焦虑的集中释放。如今，西贝仿佛陷入"多做多错"的困境，无论是员工还是顾客，都显得 格外敏感。走进西 ...

Core Insights - The company, Kanglong Chemical, reported a revenue increase but a decline in net profit for the first half of 2025, with revenue reaching 6.441 billion yuan, a year-on-year growth of 14.93%, while net profit fell to 701 million yuan, a decrease of 37.0% [1] Financial Performance - The net profit margin decreased from 19.32% in the first half of 2024 to 10.13% in 2025, a drop of 9.19 percentage points, while the gross profit margin improved from 33.39% to 33.97% [3] - The return on equity (ROE) was 4.97%, down by 3.57 percentage points year-on-year [3] Operational Efficiency - The inventory turnover days were 51.25 days, a decrease of 1.81% compared to the first half of 2024, indicating improved inventory management efficiency [5] - The net cash flow from operating activities was 1.408 billion yuan, a year-on-year increase of 3.09% from 1.1 billion yuan in the same period of 2024 [5] - The asset-liability ratio for the first half of 2025 was 40.99%, an increase of 0.44 percentage points year-on-year [5] Institutional Holdings - As of the first half of 2025, the number of institutions holding Kanglong Chemical's stock decreased to 34, down by 315 from 349 in the same period of 2024, indicating a decline in investor confidence [8] - The company's market capitalization peaked at 194.307 billion yuan on August 5, 2021, and currently stands at 53.364 billion yuan, requiring a 264.12% increase in stock price to reach its historical high [8] - Despite the decline in market capitalization, the company retains growth potential due to its professional standing in the CRMO sector and the industry's development prospects [8]

Core Viewpoint - The recent cancellation or removal of seven companies owned by Zeng Yi has attracted significant attention, raising questions about the underlying reasons and potential impacts [1]. Group 1: Business Decision Transformation - Zeng Yi's actions may stem from a strategic transformation in business, as the evolving market environment necessitates a shift from outdated business models to more promising sectors [2]. - This transformation requires precise insights into market trends, indicating that Zeng Yi's decision was likely made after careful consideration of the pros and cons [2]. Group 2: Operational Challenges - Companies often face numerous operational challenges, such as intense market competition leading to significant declines in performance and limited profits, which can hinder daily operations [3]. - Issues like cash flow disruptions may force companies to withdraw or be removed, suggesting that Zeng Yi's decision to reduce losses was a prudent business move [3]. Group 3: Legal Compliance Issues - Companies must adhere strictly to relevant laws and regulations; failure to do so can result in cancellation of registration or removal due to legal compliance challenges, including tax issues and regulatory violations [4]. - Encountering legal challenges can not only harm a company's reputation but also lead to severe legal penalties, which could have financial repercussions for Zeng Yi's enterprises [4]. Group 4: Team Collaboration Issues - The growth of a company relies on effective team collaboration; internal disputes can hinder progress and lead to operational difficulties [7]. - Instability within the team can obstruct the effective implementation of corporate strategies, potentially putting the company's sustainability at risk [7]. Group 5: Future Development Path - Despite the cancellation or removal of these companies, Zeng Yi's future development path remains a topic of interest, with potential for leveraging accumulated business knowledge to create new ventures [8]. - Observers are curious whether Zeng Yi will continue to focus on familiar industries or venture into emerging fields, making his next steps worthy of attention [8].

Operating Overview - The total operating revenue of ST Longjin (002750) for 2024 was 66.48 million yuan, a year-on-year decrease of 23.25% [2] - The net profit attributable to shareholders was -41.44 million yuan, an increase of 41.58% year-on-year; the net profit after deducting non-recurring gains and losses was -50.46 million yuan, up 37.78% year-on-year [2] - Despite poor annual performance, the fourth quarter showed improvement with total operating revenue of 19.87 million yuan, a year-on-year increase of 27.65% [2] Profitability Analysis - The company's profitability improved in 2024, with a gross margin of 64.25%, an increase of 5.53% year-on-year [3] - The net profit margin was -70.66%, an increase of 27.36% year-on-year, indicating that the company remains in a loss position [3] Cost and Expense Analysis - Total sales, management, and financial expenses amounted to 66.58 million yuan, accounting for 100.15% of revenue, a decrease of 7.73% year-on-year [4] - The reduction in sales expenses was primarily due to the implementation of centralized procurement price linkage policies in non-centralized procurement provinces [4] Cash Flow Situation - The operating cash flow per share was -0.09 yuan, an increase of 12.8% year-on-year, indicating some improvement [5] - However, the average operating cash flow over the past three years relative to current liabilities was -78.8%, suggesting ongoing concerns regarding cash flow [5] Asset and Liability Situation - The company's cash and cash equivalents amounted to 262 million yuan, a year-on-year increase of 24.2%, indicating a healthy cash position [6] - Accounts receivable decreased by 27.86% year-on-year to 8.75 million yuan, reflecting improved collection [6] Development Prospects and Risks - The company has been deeply involved in the pharmaceutical manufacturing industry for many years, holding nearly 40 domestic and foreign invention patents [7] - However, the product structure remains single, with revenues from other chemical generic drugs being relatively small [7] - The company faces multiple risks, including industry policy changes, research and development innovation, management, and safety and environmental protection [7] Summary - Overall, ST Longjin showed some recovery in profitability in 2024, but the overall operating condition remains under significant pressure [8] - The company needs to further optimize its product structure, enhance market competitiveness, and strengthen cash flow management and risk prevention for sustainable development [8]